The estimated Net Worth of Russell J. Cox is at least $4.66 million dollars as of 12 February 2019. Mr. Cox owns over 7,200 units of Gossamer Bio stock worth over $6,408 and over the last 14 years he sold GOSS stock worth over $4,320,885. In addition, he makes $337,437 as Independent Director at Gossamer Bio.
Russell has made over 18 trades of the Gossamer Bio stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 7,200 units of GOSS stock worth $115,200 on 12 February 2019.
The largest trade he's ever made was exercising 54,800 units of Gossamer Bio stock on 11 January 2012 worth over $1,220,396. On average, Russell trades about 2,859 units every 47 days since 2011. As of 12 February 2019 he still owns at least 7,200 units of Gossamer Bio stock.
You can see the complete history of Mr. Cox stock trades at the bottom of the page.
Russell J. Cox serves as Independent Director of the Company. From January 2018 until January 2019, he served as the Chief Executive Officer and a member of the board of directors of Vital Therapies, Inc., a biotechnology company. Between May 2014 and January 2018, he served as the Executive Vice President and Chief Operating Officer of Jazz Pharmaceutical plc, or Jazz, with responsibility for global commercial activities, research and development, manufacturing and technical operations, new product planning and global molecule leadership. Prior to that, Mr. Cox served as Jazz’s Executive Vice President and Chief Commercial Officer from March 2012 until May 2014. Earlier, he served in a variety of senior management roles at Jazz, which he joined in 2010. Previously, Mr. Cox served as Senior Vice President and Chief Commercial Officer of Ipsen Group, a pharmaceutical company, from January 2009 to January 2010. From 2007 until December 2008, he was Vice President of Marketing at Tercica, Inc. prior to its acquisition by Ipsen Group. From 2003 to 2007, he served as Vice President, Marketing with Scios Inc., which was acquired by Johnson & Johnson in 2003. Before 2003, Mr. Cox spent 12 years with Genentech, where he was a Product Team Leader responsible for the growth hormone franchise and led numerous product launches as a Group Product Manager. Mr. Cox has served on the board of directors of Aeglea BioTherapeutics, Inc., a biotechnology company, since 2015 and as Chairman of the board of directors of Aeglea since January 2019. Mr. Cox received a B.S. in biomedical science from Texas A&M University.
As the Independent Director of Gossamer Bio, the total compensation of Russell Cox at Gossamer Bio is $337,437. There are 10 executives at Gossamer Bio getting paid more, with Jakob Dupont having the highest compensation of $3,530,450.
Russell Cox is 56, he's been the Independent Director of Gossamer Bio since 2018. There are 6 older and 10 younger executives at Gossamer Bio. The oldest executive at Gossamer Bio, Inc. is Thomas Daniel, 66, who is the Independent Director.
Russell's mailing address filed with the SEC is 3013, Science Park Road, Torrey Pines, San Diego, San Diego County, California, 92121, United States.
Over the last 6 years, insiders at Gossamer Bio have traded over $10,765,709 worth of Gossamer Bio stock and bought 2,039,396 units worth $4,494,757 . The most active insiders traders include Kristina Burow, Faheem Hasnain et Fund V, L.P.Omega Fund V Gp.... On average, Gossamer Bio executives and independent directors trade stock every 33 days with the average trade being worth of $40,853. The most recent stock trade was executed by Richard Aranda on 24 June 2024, trading 1,908 units of GOSS stock currently worth $1,259.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio executives and other stock owners filed with the SEC include: